MGNX
Macrogenics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 2
stock price surged significantly
Revenue Plunges
EPS Beats Expectation
Revenue Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About MGNX
Macrogenics, Inc.
A biopharmaceutical company that focused on innovative monoclonal antibody-based therapeutics for the treatment of cancer
Biological Technology
08/14/2000
10/10/2013
NASDAQ Stock Exchange
341
12-31
Common stock
9704 Medical Center Drive, Rockville, Maryland 20850
--
Macrogenics, Inc., was incorporated in Delaware on August 14, 2000. The Company is a clinical-stage biopharmaceutical company focused on the discovery, development, manufacture and commercialization of innovative antibody therapies for the treatment of cancer. The company develops product candidates through its proprietary suite of next-generation antibody technology platforms and believes this platform can improve the performance of monoclonal antibodies and antibody-derived molecules. With knowledge of disease biology and immune-mediated mechanisms, the company has identified these product candidates that may address the challenges posed by specific diseases that cannot be treated by existing therapies. The company not only develops differentiated molecules for new cancer targets, but also improves the efficacy of marketed drugs.
Company Financials
EPS
MGNX has released its 2024 Q4 earnings. EPS was reported at -0.25, versus the expected -0.59, beating expectations. The chart below visualizes how MGNX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
MGNX has released its 2024 Q4 earnings report, with revenue of 19.35M, reflecting a YoY change of 80.53%, and net profit of -15.42M, showing a YoY change of 66.53%. The Sankey diagram below clearly presents MGNX’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available